Recently published research highlights the transformative potential of DNA methylation and hydroxymethylation sequencing technologies in enabling early cancer detection. By profiling methylation patterns such as 5-methylcytosine and 5-hydroxymethylcytosine, clinicians can identify aberrant epigenetic modifications that herald malignancy prior to overt tumor growth. This approach, leveraging precise epigenetic markers, advances diagnostic sensitivity and specificity, offering substantial improvements over traditional detection methods for early-stage cancer intervention.